Long‐Term Efficacy, Safety, and Tolerability of Alirocumab in 8242 Patients Eligible for 3 to 5 Years of Placebo‐Controlled Observation in the ODYSSEY OUTCOMES Trial
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-09-01
|
| Series: | Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease |
| Subjects: | |
| Online Access: | https://www.ahajournals.org/doi/10.1161/JAHA.122.029216 |
| _version_ | 1797632593098702848 |
|---|---|
| author | Shaun G. Goodman Philippe Gabriel Steg Yann Poulouin Deepak L. Bhatt Vera A. Bittner Rafael Diaz Genevieve Garon Robert A. Harrington J. Wouter Jukema Garen Manvelian Wanda Stipek Michael Szarek Harvey D. White Gregory G. Schwartz |
| author_facet | Shaun G. Goodman Philippe Gabriel Steg Yann Poulouin Deepak L. Bhatt Vera A. Bittner Rafael Diaz Genevieve Garon Robert A. Harrington J. Wouter Jukema Garen Manvelian Wanda Stipek Michael Szarek Harvey D. White Gregory G. Schwartz |
| author_sort | Shaun G. Goodman |
| collection | DOAJ |
| first_indexed | 2024-03-11T11:39:07Z |
| format | Article |
| id | doaj.art-e884e0e0649f4d2c9f494d28f4382e5d |
| institution | Directory Open Access Journal |
| issn | 2047-9980 |
| language | English |
| last_indexed | 2024-03-11T11:39:07Z |
| publishDate | 2023-09-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease |
| spelling | doaj.art-e884e0e0649f4d2c9f494d28f4382e5d2023-11-10T10:23:41ZengWileyJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease2047-99802023-09-01121810.1161/JAHA.122.029216Long‐Term Efficacy, Safety, and Tolerability of Alirocumab in 8242 Patients Eligible for 3 to 5 Years of Placebo‐Controlled Observation in the ODYSSEY OUTCOMES TrialShaun G. Goodman0Philippe Gabriel Steg1Yann Poulouin2Deepak L. Bhatt3Vera A. Bittner4Rafael Diaz5Genevieve Garon6Robert A. Harrington7J. Wouter Jukema8Garen Manvelian9Wanda Stipek10Michael Szarek11Harvey D. White12Gregory G. Schwartz13Canadian VIGOUR Centre University of Alberta Alberta Edmonton CanadaUniversité Paris‐Cité, INSERM (Institut National de la Santé Et de la Recherche Médicale) U1148, and Assistance Publique–Hôpitaux de Paris, Hôpital Bichat Paris FranceIT&M Stats Neuilly‐sur‐Seine FranceMount Sinai Heart, Icahn School of Medicine at Mount Sinai NY New York USADivision of Cardiovascular Disease University of Alabama at Birmingham AL Birmingham USAEstudios Cardiológicos Latinoamérica Instituto Cardiovascular de Rosario Rosario ArgentinaSanofi Quebec Montreal CanadaStanford Center for Clinical Research, Department of Medicine Stanford University CA Stanford USADepartment of Cardiology Leiden University Medical Center Leiden the NetherlandsRegeneron Pharmaceuticals NY Tarrytown USASanofi NJ Bridgewater USACPC (Colorado Prevention Center) Clinical Research and Division of Cardiology University of Colorado School of Medicine CO Aurora USALane Cardiovascular Services Auckland City Hospital Auckland New ZealandUniversity of Colorado School of Medicine Colorado Aurora USAhttps://www.ahajournals.org/doi/10.1161/JAHA.122.029216cholesterolPCSK9safety |
| spellingShingle | Shaun G. Goodman Philippe Gabriel Steg Yann Poulouin Deepak L. Bhatt Vera A. Bittner Rafael Diaz Genevieve Garon Robert A. Harrington J. Wouter Jukema Garen Manvelian Wanda Stipek Michael Szarek Harvey D. White Gregory G. Schwartz Long‐Term Efficacy, Safety, and Tolerability of Alirocumab in 8242 Patients Eligible for 3 to 5 Years of Placebo‐Controlled Observation in the ODYSSEY OUTCOMES Trial Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease cholesterol PCSK9 safety |
| title | Long‐Term Efficacy, Safety, and Tolerability of Alirocumab in 8242 Patients Eligible for 3 to 5 Years of Placebo‐Controlled Observation in the ODYSSEY OUTCOMES Trial |
| title_full | Long‐Term Efficacy, Safety, and Tolerability of Alirocumab in 8242 Patients Eligible for 3 to 5 Years of Placebo‐Controlled Observation in the ODYSSEY OUTCOMES Trial |
| title_fullStr | Long‐Term Efficacy, Safety, and Tolerability of Alirocumab in 8242 Patients Eligible for 3 to 5 Years of Placebo‐Controlled Observation in the ODYSSEY OUTCOMES Trial |
| title_full_unstemmed | Long‐Term Efficacy, Safety, and Tolerability of Alirocumab in 8242 Patients Eligible for 3 to 5 Years of Placebo‐Controlled Observation in the ODYSSEY OUTCOMES Trial |
| title_short | Long‐Term Efficacy, Safety, and Tolerability of Alirocumab in 8242 Patients Eligible for 3 to 5 Years of Placebo‐Controlled Observation in the ODYSSEY OUTCOMES Trial |
| title_sort | long term efficacy safety and tolerability of alirocumab in 8242 patients eligible for 3 to 5 years of placebo controlled observation in the odyssey outcomes trial |
| topic | cholesterol PCSK9 safety |
| url | https://www.ahajournals.org/doi/10.1161/JAHA.122.029216 |
| work_keys_str_mv | AT shaunggoodman longtermefficacysafetyandtolerabilityofalirocumabin8242patientseligiblefor3to5yearsofplacebocontrolledobservationintheodysseyoutcomestrial AT philippegabrielsteg longtermefficacysafetyandtolerabilityofalirocumabin8242patientseligiblefor3to5yearsofplacebocontrolledobservationintheodysseyoutcomestrial AT yannpoulouin longtermefficacysafetyandtolerabilityofalirocumabin8242patientseligiblefor3to5yearsofplacebocontrolledobservationintheodysseyoutcomestrial AT deepaklbhatt longtermefficacysafetyandtolerabilityofalirocumabin8242patientseligiblefor3to5yearsofplacebocontrolledobservationintheodysseyoutcomestrial AT veraabittner longtermefficacysafetyandtolerabilityofalirocumabin8242patientseligiblefor3to5yearsofplacebocontrolledobservationintheodysseyoutcomestrial AT rafaeldiaz longtermefficacysafetyandtolerabilityofalirocumabin8242patientseligiblefor3to5yearsofplacebocontrolledobservationintheodysseyoutcomestrial AT genevievegaron longtermefficacysafetyandtolerabilityofalirocumabin8242patientseligiblefor3to5yearsofplacebocontrolledobservationintheodysseyoutcomestrial AT robertaharrington longtermefficacysafetyandtolerabilityofalirocumabin8242patientseligiblefor3to5yearsofplacebocontrolledobservationintheodysseyoutcomestrial AT jwouterjukema longtermefficacysafetyandtolerabilityofalirocumabin8242patientseligiblefor3to5yearsofplacebocontrolledobservationintheodysseyoutcomestrial AT garenmanvelian longtermefficacysafetyandtolerabilityofalirocumabin8242patientseligiblefor3to5yearsofplacebocontrolledobservationintheodysseyoutcomestrial AT wandastipek longtermefficacysafetyandtolerabilityofalirocumabin8242patientseligiblefor3to5yearsofplacebocontrolledobservationintheodysseyoutcomestrial AT michaelszarek longtermefficacysafetyandtolerabilityofalirocumabin8242patientseligiblefor3to5yearsofplacebocontrolledobservationintheodysseyoutcomestrial AT harveydwhite longtermefficacysafetyandtolerabilityofalirocumabin8242patientseligiblefor3to5yearsofplacebocontrolledobservationintheodysseyoutcomestrial AT gregorygschwartz longtermefficacysafetyandtolerabilityofalirocumabin8242patientseligiblefor3to5yearsofplacebocontrolledobservationintheodysseyoutcomestrial |